Galapagos N.V./ BE0003818359 /
| 2024-07-18 3:30:03 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 24.5500USD | - | 2 Turnover: 49.1000 |
-Bid Size: - | -Ask Size: - | 1.78 bill.USD | - | - |
Newsfile Corp
10-25
Trundless Expands Focus on Ecuador as a Top 2024 Travel Spot for Nature and Culture
Newsfile Corp
09-06
Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment
GlobeNewswire
08-23
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire
08-01
Galapagos reports half-year 2024 financial results and provides second quarter business update
GlobeNewswire
06-14
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
05-30
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
05-15
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
04-30
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...
GlobeNewswire
04-04
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
03-28
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GlobeNewswire
03-26
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GlobeNewswire
02-22
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...
GlobeNewswire
01-04
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
